Skip to content

Cash ratio at other companies

AbbVie logo
AbbVieABBV
0.2×+0.1×
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
4.4×-1.8×
Axsome Therapeutics logo
Axsome TherapeuticsAXSM
0.7×-0.5×
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
0.3×-0.1×
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
0.3×-1.2×
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
0.9×+0.2×

Other financials

Income statement

See full
Revenue$207.7M+38.6%
Gross profit$184.3M+37.5%
Operating income-$8.3M+18.8%
Net income-$2.3M+80.6%
EPS (diluted)-$0.04+81.0%

Balance sheet

See full
Cash & equivalents$186.3M+60.8%
Total debt$40.9M+26.6%
Total equity$1.1B+4.5%
Total assets$1.5B+11.4%

Cash flow

See full
Operating cash flow$66.5M+117%
CapEx--100%
Free cash flow$66.5M+120%

Valuation

See full
Market cap$2.58B+62.8%
Enterprise value$2.44B+62.3%
P/S3.3×+0.9×

Profitability

See full
Gross margin89.4%+1.0pp
Operating margin-7.8%-18.9pp
Net margin-3.7%-13.0pp
FCF margin27.9%+3.4pp

Returns & leverage

See full
Return on equity-2.8%-9.1pp
Debt / equity0.0×
Current ratio-0.5×

Where this comes from

Calculated from Supernus Pharmaceuticals’s reported figures.

Based on the most recent quarter.

The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Supernus Pharmaceuticals's cash ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Supernus Pharmaceuticals's cash ratio?
Supernus Pharmaceuticals (SUPN) reported cash ratio of 0.5× in Q1 2026.
How has Supernus Pharmaceuticals's cash ratio changed year-over-year?
Supernus Pharmaceuticals's cash ratio increased by 21.2% year-over-year, from 0.4× to 0.5×.
What is the long-term trend for Supernus Pharmaceuticals's cash ratio?
Over 5 years (2020 to 2025), Supernus Pharmaceuticals's cash ratio has grown at a -20.1% compound annual growth rate (CAGR), from 1.2× to 0.4×.
What does cash ratio mean?
Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.